U.S. markets closed

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0900+0.0100 (+0.48%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.0800
Open2.1100
Bid2.0900 x 2900
Ask2.1000 x 3200
Day's Range1.7950 - 2.1400
52 Week Range0.4600 - 3.6800
Volume11,120,687
Avg. Volume3,730,598
Market Cap328.193M
Beta (5Y Monthly)2.51
PE Ratio (TTM)N/A
EPS (TTM)-0.2150
Earnings DateMar 10, 2021 - Mar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
    GlobeNewswire

    Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

    -- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET -- CHESTERBROOK, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2020, prior to the market open on Tuesday, March 9th, 2021. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Bob Yoder, SVP and Chief Commercial Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer. Additionally, Dr. Gregory Hammer, Professor of Anesthesiology, Stanford University Medical Center, will be providing additional remarks on the role of OLINVYK™ (oliceridine) injection in acute pain management and key considerations in the formulary review process at his institution. Title:Trevena Fourth Quarter & Full Year 2020 Financial Results Conference Call & WebcastDate:Tuesday, March 9, 2021Time:8:00 a.m. ETConference Call Details:Toll-Free: 855-465-0180International: 484-756-4313Conference ID: 7276985Webcast:https://edge.media-server.com/mmc/p/z467y594 The webcast will be available starting 15 minutes prior to the conference call start time. A replay of the webcast will be accessible following the conclusion of the live broadcast on the company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar. The Company today also announced that Carrie Bourdow will participate on a panel hosted by Scott Gottlieb, M.D., Former FDA Commissioner (2017-2019), as part of the H.C. Wainwright Global Life Sciences Virtual Conference. Additional details are below: Title:Reimbursement and Pricing – Pre- and Post-Commercialization ConsiderationsDate:Tuesday, March 9, 2021Time:1:00 p.m. ETWebcast:https://journey.ct.events/view/77c19841-d2aa-433e-8447-a47e4dde66de About TrevenaTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders. For more information, please visit www.trevena.com. Investor Contact:Dan Ferry - Managing DirectorLifeSci Advisors, LLCIR@trevena.com (617) 430-7576 Company Contact:Bob YoderSVP and Chief Commercial OfficerTrevena, Inc.(610) 354-8840

  • Trevena, Inc. to Participate in March Virtual Investor Conferences
    GlobeNewswire

    Trevena, Inc. to Participate in March Virtual Investor Conferences

    CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences in March. Additional details are below: H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9thFormat: One-on-one investor meetingsAttendees: Carrie Bourdow, President & Chief Executive OfficerBarry Shin, SVP & Chief Financial OfficerMark A. Demitrack, M.D., SVP & Chief Medical Officer Oppenheimer 31st Annual Healthcare Conference Date: Tuesday, March 16th Format: Corporate Presentation & One-on-one investor meetingsTime: 3:50 p.m. ETAttendees: Carrie Bourdow, President & Chief Executive OfficerBarry Shin, SVP & Chief Financial OfficerMark A. Demitrack, M.D., SVP & Chief Medical OfficerWebcast: https://wsw.com/webcast/oppenheimer9/trvn/2777522 A link to the webcast for the Oppenheimer presentation will be available on the Events page of the Investors section of the Company’s website at: https://www.trevena.com/investors/events-presentations/ir-calendar. A replay of the presentation will be archived on the website and available for approximately 90 days following the event. About TrevenaTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders. For more information, please visit www.Trevena.com. Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law. Investor Contact:Daniel FerryLifeSci AdvisorsPhone: 617-430-7576Email: IR@trevena.com Company Contact:Bob Yoder, SVP and Chief Commercial OfficerTrevena, Inc.Phone: 610-354-8840

  • Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference
    GlobeNewswire

    Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    CHESTERBROOK, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST. Presentation DetailsDate:Friday, February 26, 2021Time:8:40 a.m. Eastern TimePresenter:Bob Yoder, Senior Vice President and Chief Commercial OfficerWebcast:https://wsw.com/webcast/svbleerink47/trvn/2707456 A link to the webcast will be available on the Events page of the Investors section on the Company’s website at www.trevena.com/investors/events-presentations/ir-calendar. About Trevena Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders. For more information, please visit www.Trevena.com. Investor Contact:Daniel FerryLifeSci AdvisorsPhone: 617-430-7576Email: IR@trevena.com Company Contact:Bob Yoder, SVP and Chief Commercial OfficerTrevena, Inc.Phone: 610-354-8840